Introduction
============

Kawasaki disease (KD), also known as skin-mucosal-associated lymphoid syndrome (a vasculitis syndrome), is a rare childhood illness that affects the blood vessels ([@b1-etm-0-0-3492]). The disease is most common in children and can be extremely harmful to infants. Damage may occur to coronary arteries and to the heart muscle itself ([@b1-etm-0-0-3492]). Affected children may suffer from systemic small and middle-sized vascular inflammation which can be transformed into coronary artery sustainable expansion ([@b2-etm-0-0-3492]), coronary artery aneurysm and even death.

The causative factors of Kawasaki disease are unknown and the disease does not appear to be hereditary or contagious. Identifying treatment for Kawasaki disease has become the focus of investigations worldwide ([@b3-etm-0-0-3492]). Results obtained from prior studies ([@b4-etm-0-0-3492]) showed that intravenous immunoglobulin (IVIG) therapy is effective with regard to the adverse effects of Kawasaki disease, however the underlying mechanism remains to be determined. Suzuki *et al* ([@b5-etm-0-0-3492]) showed that serum 25-hydroxyvitamin D~3~ \[25-(OH)D~3~\] in blood ameliorates the immune system and prevents coronary artery abnormalities. Results from another related study ([@b6-etm-0-0-3492]) suggested that interleukin-6 (IL-6) was correlated with immunoreaction and had multiple effects such as stimulating and activating the proliferation of B cell, promoting antibody secretion, stimulating the proliferation of T cells and CTL activation ([@b7-etm-0-0-3492]). IL-6 affects the expression of acute phase protein in hepatic cells, which are involved in inflammatory reactions and accelerating cell development ([@b8-etm-0-0-3492]).

In the present study, we investigated the significance of serum 25-(OH)D~3~ and IL-6 levels prior to and after immunoglobulin treatment in children suffering from Kawasaki disease. We aimed to provide some theoretical and practical references for the successful treatment of Kawasaki disease in children.

Materials and methods
=====================

### General materials

From February, 2013 to February, 2015, 45 patients with Kawasaki disease, including 24 men and 21 women with an average age of 3.2±3 years, were enrolled in the present study, and constituted the observation group. The normal control group comprised 43 healthy volunteers during the same period. The normal control group comprised 22 men and 21 women with an average age of 2.9±2.7 years. The feverish control group comprised 46 patients (22 men and 24 women), with an average age of 3.1±2.9 years, and had respiratory infection and fever.

The aims of the study were established in accordance with relevant diagnostic criteria of Kawasaki disease presented by Japan KD Research Committee. The present study was approved by the ethics committee of Xuzhou Children\'s Hospital. Written informed consent was obtained from the patients and/or guardians.

### Methods

Venous blood (4 ml) was collected from each case prior to treatment. Samples were centrifuged at 2,000 × g for 5 min at 4°C and the upper layer of the serum was collected and transferred into a cryogenic tube (Suzhou Alpha Biotech Co., Ltd, Suzhou, China) and kept at −80°C ([@b1-etm-0-0-3492]) and the content of 25-(OH)D~3~ and IL-6 were verified. Antibodies used in this study were purchased from Roche Diagnostics (Basel, Switzerland), and RNA extraction kits were purchased from Takara Bio (Dalian, China). Patients were then treated with IVIG therapy (2 g/kg intravenous drip and oral aspirins, 2--5 days after the fever subsided). The serum was kept and the content of 25-(OH)D~3~ and IL-6 was detected.

### RT-polymerase chain reaction (PCR)

#### RNA extraction

Cryophylactic tissue samples (0.1 g) were extracted from the liquid nitrogen and melted on ice. Subsequently, 0.45 ml of RNA Plus was added and the tissues were ground in a precooled mortar and transferred into a 1.5-ml Eppendorf tube (Hamburg, Germany). After adding 0.45 ml of RNA Plus in the mortar, the samples were washed in centrifuge tube and 200 µl chloroform was then added. The samples were vigorously agitated using a vortex for 15 sec and kept on ice for 15 min. The samples were centrifuged at 8,000 × g for 15 min at 4°C and the upper layer of the serum was collected in an Eppendorf tube (RNase-treated). Isopropanol (equivalent) was added to the tube and after mixing it was left on for 10 min. The samples were centrifuged again at 8,000 × g for 10 min at 4°C and the upper layer of the serum was removed. Then, 750 µl of ethyl alcohol (75%) was added and mixed gently followed by further centrifugation at 8,000 × g at 4°C for 10 min. The upper layer of the serum was discarded and residual ethyl alcohol was removed. The quality of extracted RNA was verified and RNA was stored to be used in reverse transcription.

#### Fluorescent quantitative PCR

Fluorescent quantitative PCR kits were carried out as per the manufacturer\'s instructions (Takara), with slight modification ([Table I](#tI-etm-0-0-3492){ref-type="table"}).

#### Enzyme-linked immunosorbent assay (ELISA)

The standard protocol for the ELISA kit was carried out, with some improvements ([@b9-etm-0-0-3492]). 25-(OH)D~3~ and IL-6 were diluted at a ratio of 1:40 using the assay buffer and designed the standard curve. Samples were diluted (1:100) and 80 µl of test solution and 60 µl of detection solution were added into each well (96-wells). After 1 h incubation at 25°C, TMB chromogenic substrate was added. The light absorption value was measured at 495 nm using a microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA) and the concentration of 25-(OH)D~3~ and IL-6 was calculated using the standard curve.

#### Western blotting

An animal cell protein extraction kit was used to extract the total protein \[standard protocol carried out with some improvement ([@b10-etm-0-0-3492])\].

#### Statistical analysis

We used SPSS 20.2 software (Chicago, IL, USA) for statistical analyses. Measurement data were presented as mean ± SD, and countable data were expressed by the number of cases or the percentage. Intergroup comparison was carried out using the χ^2^ test. P\<0.05 indicated the difference was statistically significant.

Results
=======

### 25-(OH)D~3~ and IL-6 levels in the serum prior to treatment

We detected the 25-(OH)D~3~ and IL-6 levels in the serum samples collected from the three groups prior to treatment with immunoglobulin ([Fig. 1](#f1-etm-0-0-3492){ref-type="fig"}). The results showed that the content of serum 25-(OH)D~3~ in the feverish control group was lower than that of the normal control group. By contrast, the level of serum 25-(OH)D~3~ in the observation group was higher than that of the normal control group. The differences were statistically significant (P\<0.05). The level of serum 25-(OH)D~3~ in the feverish control group was lower than that of serum IL-6 in the normal children, but there were no statistically significant differences (P\>0.05). The level of serum 25-(OH)D~3~ in the observation group was higher than the content of serum IL-6 in the normal children, and the difference was statistically significant (P\<0.05). The 25-(OH)D~3~ and IL-6 gene expression levels in the three groups prior to treatment with immunoglobulin showed the same pattern observed in the protein expression ([Fig. 2](#f2-etm-0-0-3492){ref-type="fig"}).

### 25-(OH)D~3~ and IL-6 gene expression levels after immunoglobulin treatment

We measured 25-(OH)D~3~ and IL-6 gene expression levels in the three groups after immunoglobulin treatment ([Table II](#tII-etm-0-0-3492){ref-type="table"}) and observed a significant increase in serum 25-(OH)D~3~ levels compared with the levels prior to treatment and the differences were statistically significant (P\<0.05). In the observation group, after immunoglobulin treatment, the IL-6 level in serum was lower compared with the level before treatment, albeit the difference was not statistically significant (P\>0.05). The IL-6 level in the observation group after immunoglobulin treatment had no significant difference compared to that in the normal control and feverish control groups (P\>0.05). The 25-(OH)D~3~ and IL-6 expression levels were measured using western blotting ([Fig. 3](#f3-etm-0-0-3492){ref-type="fig"}). The results were comparable to those obtained from ELISA and RT-PCR.

### Correlation between 25-(OH)D~3~ and IL-6 expression in the observation group prior to and after treatment

Before treatment, levels of 25-(OH)D~3~ and IL-6 in the observation group were positively correlated (R^2^=0.9563) ([Fig. 4A](#f4-etm-0-0-3492){ref-type="fig"}). However, no significant correlation was established for levels after treatment of 25-(OH)D~3~ and IL-6 ([Fig. 4B](#f4-etm-0-0-3492){ref-type="fig"}).

### Correlation between 25-(OH)D~3~ and IL-6 and the disease course in the observation group

Our results showed that the pathogenic condition of patients in the observation group was aggravated with time and the level of 25-(OH)D~3~, and also increased with time whereas the content of IL-6 protein remained unchanged in the course of the disease ([Fig. 5](#f5-etm-0-0-3492){ref-type="fig"}).

Discussion
==========

Kawasaki disease is a serious threat to infant health and growth ([@b11-etm-0-0-3492]). Related data ([@b12-etm-0-0-3492]) have shown that despite advances in studies and treatment of Kawasaki disease, the exact pathogenesis of this disease remains to be determined and there is therefore no effective treatment method that can be utilized ([@b13-etm-0-0-3492]). It has been shown that T cells in patients with Kawasaki disease are abnormally active ([@b14-etm-0-0-3492]). Additionally, it has been established that T cells, to a large extent, can enhance the immunity and improve the organism\'s resistance against various illnesses ([@b15-etm-0-0-3492]). The results obtained from related studies have shown that the overactive T cell can interact with mononuclear cells and stimulate the overexpression of different cytokines and inflammatory substances that can damage the blood vessels ([@b16-etm-0-0-3492],[@b17-etm-0-0-3492]). To shed some light on the subject of the pathogenesis of Kawasaki disease\'s, it is extremely important to investigate any possible connection between this disease and the level of cytokines.

Vitamin D is an important signal molecule in human body that is involved in the regulation of cellular signal substances such as calcium and phosphorus, cytomembrane elements, and immunoreaction such as inhibiting the abnormal proliferation of body T/B lymphocyte ([@b18-etm-0-0-3492]). Kudo *et al* ([@b4-etm-0-0-3492]) demonstrated that in coronary endothelial cells, 25-(OH)D~3~ inhibited the release of IL-8 and the expression of cell adhesion molecule-1 induced by TNF-α. However, it could not affect the level of IL-6. It has been shown that a specific amount of 25-(OH)D~3~ is needed for regulating KD coronary artery inflammation ([@b19-etm-0-0-3492]).

By measuring the 25-(OH)D~3~ and IL-6 mRNA and protein in different groups prior to treatment, we showed that serum 25-(OH)D~3~ and IL-6 levels in the feverish control group were significantly lower than those in the normal control group. The level of 25-(OH)D~3~ in the serum of children in the observation group was significantly higher than the level observed in the normal control group. The level of 25-(OH)D~3~ in the feverish control group was lower than the level of IL-6 in the normal children, but the difference was not statistically significant (P\>0.05) while the content of 25-(OH)D~3~ in the observation group was significantly higher than the content of serum IL-6 in the normal children. The results also revealed that before treatment 25-(OH)D~3~ and IL-6 levels were positively correlated (R^2^=0.9563). The same comparison did not reveal any significant correlation between 25-(OH)D~3~ and IL-6 levels after treatment. By measuring 25-(OH)D~3~ in the serum of children patients with Kawasaki disease in different courses of disease, we showed that the pathogenic condition aggravated with time and the level of 25-(OH)D~3~ was also increased significantly. This finding suggested that 25-(OH)D~3~ is involved in the occurrence of Kawasaki disease in children and may be involved in the aggravation of the disease to some extent.

###### 

The levels of (A) 25-(OH)D~3~ and (B) IL-6 in the serum in the normal control, feverish control and observation groups prior to treatment with immunoglobulin. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.
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###### 

The (A) 25-(OH)D3 and (B) IL-6 mRNA expression level in normal control, feverish control and observation groups before immunoglobulin treatment. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.
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![25-(OH)D3 and IL-6 proteins levels in the observation group before treatment. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.](etm-12-03-1476-g04){#f3-etm-0-0-3492}

###### 

(A and B) Correlation between the 25-(OH)D3 gene expression and that of IL-6 in the observation group prior to and after treatment. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.
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![Correlation between the disease course and level of 25-(OH)D~3~ and IL-6 in patients with Kawasaki disease. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.](etm-12-03-1476-g07){#f5-etm-0-0-3492}

###### 

Fluorescent quantitative PCR primers.

  Gene          Primer sequences (5′-3′)   Fragment length (bp)
  ------------- -------------------------- ----------------------
  25-(OH)D~3~   F: CGATCTGCATGACTTCTTCCA   164
                R: GCTAGTACGATCATCATCTAC   
  IL-6          F: CGTAACGTTAGCGGCAGCTA    138
                R: CGTAGTCCAGGTACTAGCAG    
  GAPDH         F: GAAGGTGAAGGTCGGAGTC     226
                R: GAAGATGGTGATGGGATTTC    

PCR, polymerase chain reaction; 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6; F, forward; R, reverse.

###### 

Protein expression of 25-(OH)D~3~ and IL-6 in the serum of the patients in the observation group before treatment.

  Gene          Before treatment   After treatment   t      P-value
  ------------- ------------------ ----------------- ------ ---------
  25-(OH)D~3~   64.3±28.4          86.3±14.2         2.74   0.012
  IL-6          462.2±198.3        443.2±110.4       1.03   0.409

P\<0.05, significant difference. 25-(OH)D~3~, serum 25-hydroxyvitamin D~3~; IL-6, interleukin-6.
